ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco - health stocks hub $bntx 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2